Viewing nowNeurokay Tablets (Memantine Hydrochloride)
Memantine Hydrochloride 10mg
Tablet · Prescription medication
Youngjin Pharmaceutical Co., Ltd.

MFDS item code 200500892 · Notified 2005.09.14 · Insurance code 642400130
Treatment of moderate to severe Alzheimer's disease
This medication is used to alleviate the symptoms of patients with moderate to severe Alzheimer's disease and to slow the decline in cognitive function.
Treatment must be initiated by a physician experienced in the diagnosis and treatment of Alzheimer's dementia, and only when a caregiver is available to periodically confirm that the patient is taking the medicine. Diagnosis should be made according to currently accepted guidelines. The clinical benefit of this medicine and the patient's tolerability of treatment should be reassessed periodically. This medicine may be taken with or without food. 1. Adults Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, reach the maintenance dose by increasing the dose by 5mg per week over the first 3 weeks as follows. Week 1 (days 1~7): Administer 5mg once daily for 7 days. Week 2 (days 8~14): Administer 10mg daily (5mg twice daily) for 7 days. Week 3 (days 15~21): Administer 15mg daily (10mg in the morning and 5mg in the evening) for 7 days. From week 4: Administer 20mg daily (10mg twice daily). Maintenance dose: The recommended maintenance dose is 20mg daily (10mg twice daily). 2. Elderly patients: Based on clinical data, the recommended dose in patients 65 years of age and older is 20mg daily (10mg twice daily). 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance 30-50 mL/min), reduce the daily dose to 10mg. If well tolerated after at least 7 days of treatment, the dose may be increased to 20mg daily according to the standard dose-escalation schedule. In patients with severe renal impairment (creatinine clearance 5-30 mL/min), reduce the daily dose to 10mg. 4. Patients with hepatic impairment: No dose adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Since there are no data on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this medicine.
This medicine should not be used in patients with a known allergy to any component of this medication. It should not be administered to patients with severe liver disease or significantly impaired kidney function. Patients with lactose intolerance or certain metabolic genetic disorders should also refrain from taking this medication. Patients with epilepsy or a history of seizures should use this medicine cautiously, as the risk of side effects may increase when taken with certain drugs. Particular caution is advised when co-administering with medications that affect the central nervous system, as the risk of side effects may be increased, and consultation with a physician is essential. Patients with heart disease or uncontrolled hypertension should also be cautious when using this medication. This medication may cause side effects such as dizziness, headache, constipation, drowsiness, and hypertension; if these symptoms occur, immediate consultation with healthcare professionals is necessary. Additionally, as this medication can interact with other drugs, it is vital to inform healthcare providers about any medications currently being taken. Women who are pregnant or may become pregnant should carefully weigh the risks and benefits of using this medication, and it is recommended to discontinue breastfeeding if using this medication. Safety and efficacy have not been established for use in children and adolescents under 18 years of age. In the event of overdose, central nervous system symptoms and gastrointestinal symptoms may occur, and immediate medical attention should be sought. This medication can reduce the patient's responsiveness, so caution is advised when driving or operating machinery. Finally, this medication should be stored out of reach of children, and it is safer not to transfer it to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air exposure. It is advisable to maintain a storage temperature between 1 and 30 degrees Celsius to safely preserve the drug's effectiveness.
White, oblong, film-coated tablet
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowMemantine Hydrochloride 10mg
Tablet · Prescription medication
Youngjin Pharmaceutical Co., Ltd.
Memantine Hydrochloride 1g
Solution · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Ildong Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Donghwa Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Unimed Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Myongin Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Jinyang Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.